1. Home
  2. LGCB vs INTS Comparison

LGCB vs INTS Comparison

Compare LGCB & INTS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

LGCB

Linkage Global Inc

N/A

Current Price

$2.06

Market Cap

23.4M

Sector

N/A

ML Signal

N/A

Logo Intensity Therapeutics Inc.

INTS

Intensity Therapeutics Inc.

HOLD

Current Price

$0.51

Market Cap

24.0M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
LGCB
INTS
Founded
2011
2012
Country
Japan
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
23.4M
24.0M
IPO Year
2023
2023

Fundamental Metrics

Financial Performance
Metric
LGCB
INTS
Price
$2.06
$0.51
Analyst Decision
Strong Buy
Analyst Count
0
3
Target Price
N/A
$4.33
AVG Volume (30 Days)
76.6K
4.1M
Earning Date
07-03-2025
11-06-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$8,993,265.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
5.80
N/A
52 Week Low
$1.22
$0.19
52 Week High
$6.83
$3.17

Technical Indicators

Market Signals
Indicator
LGCB
INTS
Relative Strength Index (RSI) 55.85 57.01
Support Level $1.85 $0.35
Resistance Level $2.12 $0.42
Average True Range (ATR) 0.13 0.05
MACD 0.01 0.00
Stochastic Oscillator 65.55 88.83

Price Performance

Historical Comparison
LGCB
INTS

About LGCB Linkage Global Inc

Linkage Global Inc is a cross-border e-commerce integrated service provider. It provides international e-commerce merchants, overseas brands, import and export trading enterprises, etc. with a globally selected supply chain, digital marketing, e-commerce training, international store, ERP and e-commerce software, social e-commerce and other e-commerce integrated services. The Company has two operating segments: Extend from Japan, and Other Subsidiaries from Hong Kong. The company is Committed to building a one-stop cross-border integrated service platform to make cross-border trade easier. Company operates in Japan, Hong Kong and China, with maximum revenue from Japan.

About INTS Intensity Therapeutics Inc.

Intensity Therapeutics Inc is a clinical-stage biotechnology company pioneering a new immune-based approach to treat solid tumor cancers. The company leverages its DfuseRxtechnology platform to create new, proprietary drug formulations that, following direct injection, rapidly disperse throughout a tumor and diffuse therapeutic agents into cancer cells. Intensity's product candidates have the potential to induce an adaptive systemic immune response that not only attacks the injected tumor, but also non-injected tumors. Their pipeline is focused on realizing the full potential of INT230-6 in metastatic and local disease settings to help cancer patients with unmet medical need.

Share on Social Networks: